The American Heart Association (AHA) and the American College of Cardiology (ACC) have recently released the first guideline ...

Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Cl ...

Lysine shows promise in acute lung injury by restoring lung repair mechanisms and improving survival. Learn more about this ...

The first multisociety guidelines on the diagnosis and management of acute pulmonary embolism feature a new classification ...

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment a ...

Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

Researchers have found in a new study that the hemoglobin, albumin, lymphocyte, and platelet score serves as an independent predictor of 30-day readmission in patients with acute exacerbation ...

CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a ...

COPD breathlessness action plans may help patients manage episodes, reduce anxiety, and avoid emergency care. Read more.

Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism, which have incidence rates of between 1 and 2 cases per 1000 people for the first episode.1,2 Strong, provoking risk ...

A valved holding chamber with high drug delivery performance may reduce wheezing severity and hospitalizations more ...

The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five years. This growth is driven by the rising prevalence of respiratory diseases ...